Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher W Ryan

Showing results (111-120 of 113) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 113 results.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Journal for Immunotherapy of Cancer|June 30, 2025
Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohortSandip Pravin Patel, Jillian Fisher, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer|February 11, 2026
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervixYoung Kwang Chae, Megan Othus, Sandip P Patel, et al.
Pageof 12

Showing results (111-120 of 113) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 113 results.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Journal for Immunotherapy of Cancer|June 30, 2025
Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohortSandip Pravin Patel, Jillian Fisher, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer|February 11, 2026
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervixYoung Kwang Chae, Megan Othus, Sandip P Patel, et al.
Pageof 12